Anti-ribosomal P antibody in schizophrenia

Yaron Gilat, Yehuda Shoenfeld, Moshe Kotler, Iulian Iancu

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: A series of epidemiological, clinical and laboratory findings suggest an autoimmune process in schizophrenia and include, among others, high titers of various autoantibodies in the sera of patients. Antiribosomal P antibody is known to exist in systemic lupus erythematosus (SLE) patients with a psychiatric presentation, including psychosis, rationalizing the examination of its existence in patients with schizophrenia. Methods: Sera of 59 patients, 48 diagnosed with schizophrenia and 11 diagnosed with a schizoaffective disorder, were examined for the presence of antiribosomal P antibody titers using ELISA. The control group consisted of 94 healthy subjects with similar age and gender distribution. Results: Anti-ribosomal P antibody titers were below cut-off level in 58 patients and borderline in one patient, similar to the low titers of the control group. Conclusions: Previous investigations have demonstrated high specificity for anti-ribosomal P antibody in SLE patients with psychosis. In view of the results of this study, however, anti-ribosomal P antibody is not a biological marker for schizophrenia.

Original languageEnglish
Pages (from-to)275-279
Number of pages5
JournalIsrael Journal of Psychiatry and Related Sciences
Volume48
Issue number4
StatePublished - 1 Jan 2011
Externally publishedYes

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Fingerprint

Dive into the research topics of 'Anti-ribosomal P antibody in schizophrenia'. Together they form a unique fingerprint.

Cite this